Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Added value of dynamic SPECT/CT after kidney transplantation using a 3D-ring CZT-based camera: a case report.

EJNMMI research·2026
Same author

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The malignancy risk of thyroid incidentalomas detected by [<sup>18</sup>F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands.

European journal of nuclear medicine and molecular imaging·2026
Same author

International Consensus on the Requirements for Definitions of Complete Remission and Recurrence of Differentiated Thyroid Cancer: a Delphi Study (ICON-DTC).

European journal of endocrinology·2025
Same author

Pharmacological Enhancement of Radionuclide Therapy Using Radiopharmaceutical-Drug Combinations in Oncology.

Journal of clinical pharmacology·2025
Same author

Radiolabeling of Angiostrongylus vasorum- and Crenosoma striatum larvae: a novel method using PET/CT to unveil larval migration in the gastropod intermediate host (Lissachatina fulica).

Parasites & vectors·2025

Related Experiment Video

Updated: May 28, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.

Frederik A Verburg1, Johannes W A Smit, Inge Grelle

  • 1Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany. fverburg@ukaachen.de

Clinical Endocrinology
|October 25, 2011
PubMed
Summary
This summary is machine-generated.

Long-term levothyroxine (LT4) therapy for differentiated thyroid carcinoma (DTC) significantly alters thyroid hormone metabolism. This study found reduced total triiodothyronine and thyroxine levels, suggesting changes in deiodinase enzyme activity.

Related Experiment Videos

Last Updated: May 28, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Area of Science:

  • Endocrinology
  • Thyroidology
  • Oncology

Background:

  • Differentiated thyroid carcinoma (DTC) treatment often involves TSH-suppressive levothyroxine (LT4) therapy.
  • The long-term effects of this therapy on thyroid hormone metabolism remain incompletely understood.

Purpose of the Study:

  • To investigate alterations in thyroid hormone metabolism following extended TSH-suppressive LT4 therapy in DTC patients.
  • To analyze changes in thyroid-stimulating hormone (TSH), reverse triiodothyronine (rT3), total triiodothyronine (TT3), and total thyroxine (TT4) levels.

Main Methods:

  • A cohort of 61 DTC patients receiving TSH-suppressive LT4 therapy was studied.
  • Serum samples were analyzed from two time points: within 1 year post-ablation (time1) and after at least 3 years of continuous therapy (time2).
  • TSH, rT3, TT3, and TT4 levels were measured and their relationships analyzed.

Main Results:

  • Significant reductions in TT3, TT4, and TSH levels were observed at time2 compared to time1 (P < 0.001).
  • LT4 dose, bodyweight, and rT3 levels remained stable, but the TT4/TT3 ratio increased significantly (P < 0.001).
  • Decreases in TT4/rT3 and TT3/rT3 ratios were noted, with no age-related correlation.

Conclusions:

  • Long-term TSH-suppressive LT4 therapy induces significant changes in thyroid hormone metabolism in DTC patients.
  • These metabolic shifts are likely due to a combined downregulation of deiodinase subtypes 1 and 2, and an upregulation of deiodinase subtype 3.